Sheldon Sloan

Sheldon Sloan brings over 30 years of experience in academia and the biopharmaceutical industry, with an extensive track record in the field of gastroenterology and IBD. Prior to joining Abivax, Sheldon worked for Arena Pharmaceuticals and, after its acquisition, for Pfizer. He was Program Lead for Etrasimod UC, responsible for cross-functional leadership, planning and management, operational business process planning, and execution management of the Ulcerative Colitis program, including its global submission and launch. Before joining Arena Pharmaceuticals, Sheldon held different leadership positions at J&J in Medical Affairs, R&D, and Science Policy. In his last position at J&J, he was Global Medical Affairs Leader for IBD, leading the global launch strategy and execution for Crohn’s Disease and Ulcerative Colitis for Stelara. Sheldon also has a strong track record in bioethics and has been involved on different levels in questions addressing bioethics issues including animal care and use and human subjects research. Sheldon holds an M.D. from Rush Medical College, Chicago, USA, and a Master of Bioethics from the University of Pennsylvania, USA. He has authored a large number of scientific publications and abstracts and contributed to various books in the gastroenterology and immunology fields.